The estimated Net Worth of Michael R Minogue is at least $31.6 Millón dollars as of 23 May 2023. Mr. Minogue owns over 3,300 units of Abiomed stock worth over $4,656,445 and over the last 20 years he sold ABMD stock worth over $10,315,483. In addition, he makes $16,612,800 as Chairman of the Board, President y Chief Executive Officer at Abiomed.
Sign up
Mr. Minogue ABMD stock SEC Form 4 insiders trading
Michael has made over 44 trades of the Abiomed stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 3,300 units of ABMD stock worth $1,005,675 on 23 May 2023.
The largest trade he's ever made was selling 172,986 units of Abiomed stock on 4 April 2011 worth over $2,596,520. On average, Michael trades about 13,603 units every 42 days since 2005. As of 23 May 2023 he still owns at least 12,221 units of Abiomed stock.
You can see the complete history of Mr. Minogue stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Minogue biography
Michael R. Minogue serves as Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Michael R. Minogue has been Chairman, President and Chief Executive Officer of ABIOMED, Inc. since 2004. Mr. Minogue transitioned the Company’s mission to creating the field of heart recovery with the acquisition and development of new technologies such as the Impella®, the world’s smallest heart pump, and extracorporeal membrane oxygenation (ECMO). ABIOMED has been one of the fastest growing, GAAP profitable medtech companies and ranked the third best performing stock on the S&P 500 for the last decade. ABIOMED has earned numerous global regulatory approvals on new products and indications in the United States, Europe, Japan and other countries. ABIOMED employs approximately 1,500 people with facilities in Danvers, Massachusetts, Aachen and Berlin, Germany and Tokyo, Japan. In addition to his responsibilities at ABIOMED, Mr. Minogue currently serves on the medical device industry association board of directors for AdvaMed, and serves on the board for the Medical Device Innovation Consortium (MDIC). He also serves on Insulet Corporation’s Board of Directors and was on the boards of LifeCell and Bioventus.
What is the salary of Michael Minogue?
As the Chairman of the Board, President y Chief Executive Officer of Abiomed, the total compensation of Michael Minogue at Abiomed is $16,612,800. There are no executives at Abiomed getting paid more.
How old is Michael Minogue?
Michael Minogue is 53, he's been the Chairman of the Board, President y Chief Executive Officer of Abiomed since 2005. There are 12 older and 4 younger executives at Abiomed. The oldest executive at Abiomed Inc. is Jeannine Rivet, 72, who is the Independent Director.
What's Michael Minogue's mailing address?
Michael's mailing address filed with the SEC is C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON, MA, 01720.
Insiders trading at Abiomed
Over the last 22 years, insiders at Abiomed have traded over $148,507,587 worth of Abiomed stock and bought 232,354 units worth $4,276,073 . The most active insiders traders include Michael R Minogue, Eric A Md Rose y David M Weber. On average, Abiomed executives and independent directors trade stock every 16 days with the average trade being worth of $5,341,900. The most recent stock trade was executed by Martin P Sutter on 17 February 2022, trading 4,000 units of ABMD stock currently worth $1,258,840.
What does Abiomed do?
Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
What does Abiomed's logo look like?
Complete history of Mr. Minogue stock trades at Abiomed y Insulet
Abiomed executives and stock owners
Abiomed executives and other stock owners filed with the SEC include:
-
Michael Minogue,
Chairman of the Board, President, Chief Executive Officer -
Todd Trapp,
Chief Financial Officer, Vice President -
Andrew Greenfield,
Vice President, Chief Commercial Officer -
David Weber,
Chief Operating Officer, Senior Vice President -
Michael R. Minogue,
Chairman, CEO & Pres -
Michael Howley,
Vice President and General Manager, Global Sales -
Todd A. Trapp,
CFO & VP -
Dr. David M. Weber,
Sr. VP & COO -
Marc A. Began,
VP, Gen. Counsel & Sec. -
Andrew J. Greenfield,
VP & Chief Commercial Officer -
Dorothy Puhy,
Lead Independent Director -
Paul Thomas,
Independent Director -
Martin Sutter,
Independent Director -
Jeannine Rivet,
Independent Director -
Christopher Van Gorder,
Independent Director -
Eric Rose,
Independent Director -
Marc Began,
Vice President, General Counsel, Secretary -
Karen Mahoney,
Head of Global HR -
Michael G. Howley,
VP & GM of Global Sales -
Sarah Karr,
Communications Mang. -
Ingrid Goldberg Ward,
Director of Investor Relations -
Dr. Thorsten Siess Ph.D.,
VP & CTO -
Henri A Termeer,
Director -
Gorder Chris Van,
Director -
William J Bolt,
SVP, DA and QA -
Michael John Tomsicek,
Vice President, CFO -
W Gerald Austen,
Director -
Myron L Rolle,
Director -
Louis E Lataif,
Director -
Robert Bowen,
Chief Financial Officer -
Ronald W Dollens,
Director -
Daniel J Sutherby,
CFO -
Inc Abiomed,
Director -
Connell Desmond Jr O,
Director -
Paul Fireman,
Director -
Javier Jimenez,
VP Operations -
Anthony W Bailey,
VP, Business Development -
David M Lederman,
Chairman, CEO & President -
Charles B Haaser,
Principal Financial Officer -
Eugene D Rabe,
SVP, Global Sales & Services -
Christopher D Macdonald,
SVP Global Sales -
Sheila Marie Flaherty,
VP, General Counsel -
Robert T V Kung,
SVP, Chief Scientific Officer -
Edward E Berger,
VP, Strat. Plan & Ext. Comm. -
Patricia A. Fitch,
Vice President of Sales -
Raymond J Kelley,
VP Marketing -
David Gottlieb,
Director -
John F Obrien,
Director -
Gary Stickel,
VP of HR -
Karim Benali,
VP Product Development -
Robert Farra,
VP Engineering & Manufacturing -
Stephen C Mc Evoy,
VP and General Counsel -
Paula A Johnson,
Director